Scaling kangaroo mother care in India could save 26,000 newborns a year

Kangaroo mother care — holding a newborn skin-to-skin against a parent's chest, often for hours a day, alongside frequent breastfeeding — is one of the cheapest interventions in newborn medicine and one of the best evidenced. A modelling study published on 2 September in BMJ Global Health asks what would happen if India, which carries one of the world's largest burdens of newborn death, actually delivered it at scale [s1].

What the study did

The authors built an extended cost-effectiveness analysis — a framework that estimates not just health gained per rupee spent but who gains it and who is spared financial ruin — on top of primary data from a randomised controlled trial [s1]. They modelled scaling kangaroo mother care (KMC) to 95% coverage nationally and projected lives saved, disability-adjusted life-years (DALYs) averted, out-of-pocket expenditure avoided, and cases of catastrophic health spending prevented, broken down by socioeconomic quintile and by state [s1].

That distributional lens is the point. A conventional cost-effectiveness study can tell you an intervention is good value on average while staying silent on whether the benefits reach the people who need them most.

What it found

Scaling KMC to near-universal coverage could save around 26,000 neonatal lives each year and avert roughly 1.6 million DALYs [s1]. On the financial side, the model estimates about US$13 million in out-of-pocket expenditure avoided and an estimated 57,000 households spared catastrophic health spending — the kind of medical bill that pushes a family into poverty [s1].

The equity findings are the most striking. Three-quarters of the benefits would accrue to the lowest two socioeconomic quintiles, and six high-burden states — including Uttar Pradesh, Bihar and Madhya Pradesh — would account for 90% of the health and financial gains [s1]. In other words, the intervention concentrates its help where newborn death and financial vulnerability are already worst.

By the standard yardstick, the intervention is highly cost-effective: the incremental cost-effectiveness ratio ranged from 0.08 to 0.17 times India's gross domestic product per capita across quintiles, well below the thresholds usually used to judge value [s1]. A probabilistic sensitivity analysis found scaling up KMC would be cost-effective in 97.8% of simulations [s1].

The caveats

These are modelled projections, not observed outcomes, and their accuracy depends on the assumptions fed in — coverage that reaches 95%, effect sizes carried over from trial conditions into routine practice, and cost estimates that hold across very different states. Real-world scale-up rarely matches modelled scale-up: KMC requires trained staff, space, and support for mothers to maintain skin-to-skin contact for extended periods, none of which appears automatically because a policy says so. The authors ran deterministic and probabilistic sensitivity analyses to test how robust the findings are, which strengthens confidence, but sensitivity analysis cannot rescue a wrong central assumption.

Why it matters

The result lands on the side of an old argument in global health: that some of the largest gains come not from new technology but from delivering proven, low-cost care to the people currently missing it. KMC needs no cold chain, no patent and little equipment. The study's contribution is to attach numbers — including equity and financial-protection numbers — to what near-universal delivery in one large country might buy, and to show that the benefits would flow disproportionately to the poorest households and the highest-burden states [s1].

This article is informational and does not constitute medical advice.